Archive · 7 Aug 2025
Glenmark USA Settles Antitrust Lawsuit for $37.75 Million
Glenmark Pharmaceuticals' US arm has agreed to pay $37.75 million to settle several lawsuits.
These lawsuits claimed the company was involved in unfair business practices.
The lawsuits were filed by different groups of people.
They accused Glenmark of conspiring to keep drug prices high.
These claims involve specific drugs and wider actions with other manufacturers.
As a result of this news, the company's stock went down a little bit.
Glenmark Pharmaceuticals' USA arm reached a $37.75 million settlement.
The settlement resolves multiple US antitrust lawsuits.
Lawsuits were filed by various groups including direct purchasers.
Allegations include drug-specific and broader manufacturing conspiracies.
Shares of Glenmark Pharmaceuticals Ltd. decreased by 1.52% on the BSE.
- Who
- Glenmark Pharmaceuticals.
- What
- Glenmark Pharmaceuticals' USA arm reached a $37.75 million settlement in US antitrust lawsuit.
- When
- Not explicitly mentioned in articles.
- Where
- USA.
- Why
- To resolve multiple US antitrust lawsuits.
Plaintiffs
Glenmark
Conspiracy Allegations
Plaintiffs
Drug-specific and broader conspiracies involving multiple generic drug manufacturers.
Glenmark
Not mentioned in articles.
- Company
- Glenmark Pharmaceuticals
- Amount of Settlement
- $37.75 million
- Type of Lawsuit
- US antitrust lawsuit
- Claimants
- Direct purchasers, end-payers, indirect purchasers, and private plaintiffs
- Stock impact
- Shares decreased 1.52% on BSE